Evidence map›Paper›PMID 41923137›Full record

ReviewCancer cell international2026

Targeting cell death: a promising approach for colorectal cancer therapy.

Chengfeng Xiao, Linda Oyang, Xianjie Jiang, Shizhen Li, Qiu Peng

Abstract readReview
In one paragraph

Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chengfeng XiaoXiangya School of Medicine, Central South University, Hunan, 410013, Changsha, China.
Linda OyangXiangya School of Medicine, Central South University, Hunan, 410013, Changsha, China.
Xianjie JiangThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, 283 Tongzipo Road, Changsha, 410013, Hunan, China.
Shizhen LiThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, 283 Tongzipo Road, Changsha, 410013, Hunan, China. 2214811088@qq.com.
Qiu PengThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, 283 Tongzipo Road, Changsha, 410013, Hunan, China. pengqiu@hnca.org.cn.

Funding

National Natural Science Foundation of China 82302987
6 · The paper itself

Abstract

Colorectal cancer is one of the most common digestive malignancies worldwide. Cell death plays a crucial role in maintaining normal biological functions and homeostasis, with dysregulation of cell death leading to tumorigenesis. In addition to apoptosis, necroptosis, pyroptosis and ferroptosis, it is PANoptosis, cuproptosis and disulfidptosis that are involved in the development of CRC. Radiotherapy, chemotherapy, targeted therapy and immunotherapy are the main treatments for advanced CRC. These therapies induce CRC cell death through various pathways, including increased intracellular ROS, induced DNA damage, inhibiting the specific signaling pathways and activating the immune system. Cell death can regulate CRC cells’ sensitivity to treatment through complex mechanisms, suggesting that targeting cell death could not only inhibit rapid CRC cell proliferation but also overcome treatment resistance. This review summarizes the current understanding of various CRC mechanisms and the primary mechanisms by which existing CRC treatments induce cell death. Additionally, we highlight recent research advancements in targeting cell death for CRC treatment and describe numerous challenges encountered in clinical practice. Aiming to provide effective strategies and new perspectives for CRC treatment and to lay a solid theoretical foundation for the development of drugs targeting CRC cell death.

Indexed as

CRCDNA damageImmune therapyRCDTarget therapy

Identifiers

PMID41923137
PMCPMC13202956

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.